甲胺基甲酰氯 | 6452-47-7

• 物质功能分类: 化学农药原药 - 杀虫剂中间体
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 甲胺基甲酰氯
• 中文别名: 甲氨基甲酰氯；一甲氨基甲酰氯
• 英文名称: methylcarbamoyl chloride
• 英文别名: N-methylcarbamoyl chloride；methylcarbamic chloride；methylaminoformyl chloride；methyl carbamic acid chloride；methylcarbamyl chloride；N-methyl-carbamic acid chloride；N-methylaminoformyl chloride
• CAS: 6452-47-7
• 化学式: C₂H₄ClNO
• mdl: MFCD08703300
• 分子量: 93.5129
• InChiKey: GRRYSIXDUIAUGY-UHFFFAOYSA-N

物化性质

• 熔点：
  45°C
• 沸点：
  93°C (dec.)
• 密度：
  1.185±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于乙腈、氯仿（少量）、DMSO

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P260,P261,P264,P270,P271,P280,P301+P312,P301+P330+P331,P302+P352,P303+P361+P353,P304+P340,P305+P351+P338,P310,P312,P321,P322,P330,P363,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H302,H312,H314,H332
• 储存条件：
  | 2-8℃ |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methylaminoformyl chloride
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methylaminoformyl chloride
CAS number: 6452-47-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C2H4ClNO
Molecular weight: 93.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质

甲氨基甲酰氯纯品为白色晶体，熔点在45°C（分解），易溶于苯类等有机溶剂。遇碱或水分解时会释放大量热量，易引起爆炸，并且高温下不稳定。该物质对眼、呼吸道有刺激性。

用途

甲氨基甲酰氯广泛用作氨基甲酸酯类杀虫剂如仲丁威、克百威、异丙威、灭多威、混灭威和速灭威等的中间体，同时也是农药氨基甲酸酯杀虫剂和除草剂的重要中间体。

生产方法

甲氨基甲酰氯由甲胺与光气反应制得。具体过程如下：将40%的甲胺水溶液汽化并经干燥处理后，以1:1.3（体积比）的比例与光气混合，其中甲胺流速为4立方米/小时，光气流速为8.6立方米/小时（含量60%-70%）。将这两种气体分别预热至甲胺220-260℃、光气220-240℃后进入文氏管，在280-300℃下合成，生成气体甲氨基甲酰氯。然后通过四氯化碳（或氯苯溶液）在0-20℃下循环吸收，可得到10%左右的甲氨基甲酰氯四氯化碳（或氯苯）溶液；亦可通过冷却至35-40℃以下使产物变为液态成品。

反应方程式如下： [ \text{CH}_3\text{NH}_2 + \text{COCl}_2 \rightarrow \text{CH}_3\text{NHCOCl} ]

反应信息

• 作为反应物：
  描述：

  甲胺基甲酰氯 在 三乙胺 作用下， 以 二甲基二硫 为溶剂， 生成 异氰酸甲酯
  参考文献：
  名称：

  由 S- 甲基 N- 烷基硫代氨基甲酸酯一锅三步制备烷基和芳基烷基氨基甲酸酯

  摘要：

  描述了从相应的 S-甲基 N-烷基-硫代氨基甲酸酯开始合成烷基和芳基烷基氨基甲酸酯的一般程序。该程序由以一锅方式进行的三个步骤组成，无需分离中间体 N-烷基氨基甲酰氯或异氰酸烷基酯。所有目标产物均以高收率获得（16 例，平均收率 91%）。值得注意的是回收工业上感兴趣的副产品二甲基二硫，每摩尔硫代氨基甲酸盐的量为半摩尔，试剂的完全利用。如果需要，烷基异氰酸酯也可以以高产率分离。

  DOI：

  10.1055/s-2008-1072573
• 作为产物：
  描述：

  异氰酸甲酯 在 盐酸 作用下， 以 四氯化碳 为溶剂， 生成 甲胺基甲酰氯
  参考文献：
  名称：

  链脲佐菌素的制备合成。

  摘要：

  AbstractDurch Umsetzung von D‐Glucosamin mit dem bisher unbekannten N‐Nitroso‐methylcarbamylazid (VII) wurde das Beta‐Zytotoxin Streptozotocin (VIII) synthetisch präparativ zugänglich gemacht.

  DOI：

  10.1002/hlca.19690520837
• 作为试剂：
  描述：

  Oxycodone 、 N,N-bis(tert-butyl) N’-2-(chlorocarbonyl(methyl)amino)ethylcarbamate 在 双(三甲基硅烷基)氨基钾 、 甲胺基甲酰氯 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 3.25h， 以55%的产率得到oxycodone 6-(N-methyl-N-(2-amino)ethylcarbamate)
  参考文献：
  名称：

  Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug

  摘要：

  提供了一种名为KC-7的化合物，N-1-[(S)-2-(氧可酮-6-烯醇-羰基-甲基-氨基)-2-羰基-肌氨酸-乙胺]-精氨酸-甘氨酸-乙酸盐，或其可接受的盐、溶剂化物和水合物。本公开还提供了包含前药的组合物及其使用方法，其中组合物包含前药KC-7，该前药能够控制释放氧可酮。这样的组合物可以选择性地提供一种胰蛋白酶抑制剂，该抑制剂与介导前药控制释放氧可酮的酶相互作用，以减弱前药的酶切。

  公开号：

  US20120178773A1

文献信息

• [EN] AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINOPYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PHOSPHATIDYLINOSITOL PHOSPHATE KINASE
  申请人：PETRA PHARMA CORP

  公开号：WO2019126731A1

  公开（公告）日：2019-06-27

  The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

  这项发明涉及PI5P4K抑制剂，用于治疗癌症、神经退行性疾病、炎症性疾病和代谢性疾病，其化学式为：(I)，其中A、B、R1、X1、X2和W如本文所述。
• PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20160185785A1

  公开（公告）日：2016-06-30

  The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X 1 , X 2 , R 1 -R 5 , R 5′ and R 6 are described herein.

  这项发明涉及USP7抑制剂，用于治疗癌症、神经退行性疾病、免疫紊乱、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病、细菌感染和疾病，具有以下结构式： 其中m、n、X1、X2、R1-R5、R5'和R6如本文所述。
• POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180297994A1

  公开（公告）日：2018-10-18

  The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及肌动蛋白M2受体的阳性变构调节剂，特别是新型的7-取代的1-芳基萘啶-3-羧酰胺，以及其制备方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• [EN] 2-METHYL-QUINAZOLINES<br/>[FR] 2-MÉTHYL-QUINAZOLINES
  申请人：BAYER PHARMA AG

  公开号：WO2018172250A1

  公开（公告）日：2018-09-27

  The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.

  本发明描述了一般式(I)的2-甲基喹唑啉化合物，制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的药物组合物和组合物，以及用于制造药物组合物的该化合物的用途。一般式(I)的2-甲基取代喹唑啉化合物有效且选择性地抑制Ras-Sos相互作用，而不显著靶向EGFR受体。因此，它们对于治疗或预防疾病特别是高增殖性疾病，如癌症作为单一药剂或与其他活性成分组合使用是有用的。
• [EN] HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES<br/>[FR] HÉTÉRO-1,5,6,7-TÉTRAHYDRO-4H-INDOL-4-ONES
  申请人：BAYER PHARMA AG

  公开号：WO2017102649A1

  公开（公告）日：2017-06-22

  Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.

  本文件所述的式(I)化合物、其制备方法以及作为药物的用途。